No reference-scaling for NTIDs [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2021-08-02 14:57 (52 d 20:32 ago) – Posting: # 22498
Views: 989

Hi Prasad,

» Little bit confusion raised as the Gliclazide is a NTI molecule, what would be the study design for gliclazide 80mg tablet BE study for Europe, WHO & HKG submission.

If you are referring to Hong Kong, guidances of China’s CDE are applicable.

Adding to what vixen wrote: Reference-scaling (ABEL: the EMA, most jurisdictions including the WHO or RSABE: U.S. FDA and China’s CDE) for NTIDs is not acceptable.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,693 posts in 4,535 threads, 1,541 registered users;
online 10 (1 registered, 9 guests [including 5 identified bots]).
Forum time: Friday 11:30 CEST (Europe/Vienna)

Tortured data will confess to anything.    Fredric Menger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5